Biocryst Pharmaceuticals Inc (BCRX)

May 05, 2026

BioCryst Pharmaceuticals earnings loom amid HAE market battle By Investing.com - Investing.com Nigeria

May 05, 2026

May 05, 2026

BioCryst Pharmaceuticals earnings loom amid HAE market battle - Investing.com

May 05, 2026

May 05, 2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 05, 2026

May 05, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 05, 2026

May 04, 2026

BioCryst (BCRX) Secures Licensing Deal for Navenibart in Europe - GuruFocus

May 04, 2026

May 04, 2026

BioCryst Pharmaceuticals, Inc. Files Form 8-K with SEC – Company Details, Stock, and Contact Information (May 2026) - Minichart

May 04, 2026

May 04, 2026

BioCryst Licenses European Rights to HAE Drug Navenibart - TipRanks

May 04, 2026

May 04, 2026

BioCryst licenses navenibart rights in Europe for $70M upfront By Investing.com - Investing.com Canada

May 04, 2026

May 04, 2026

BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe. - Bitget

May 04, 2026

May 04, 2026

BioCryst (NASDAQ: BCRX) licenses navenibart in Europe for $70M upfront - Stock Titan

May 04, 2026

May 04, 2026

BioCryst lands $70M now, up to $275M more in Europe HAE deal - Stock Titan

May 04, 2026

May 04, 2026

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema - Yahoo Finance UK

May 04, 2026

May 03, 2026

Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains - Yahoo Finance

May 03, 2026

May 02, 2026

RBC Capital Raises BioCryst Pharmaceuticals Price Target to 14 Dollars - HarianBasis.co

May 02, 2026

May 01, 2026

RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech - Insider Monkey

May 01, 2026

May 01, 2026

BCRX Should I Buy - Intellectia AI

May 01, 2026

Apr 29, 2026

Vanguard Capital Management (NASDAQ: BCRX) discloses 12.96M-share stake, 5.16% - Stock Titan

Apr 29, 2026

Apr 29, 2026

5 Best Drug Stocks to Buy According to Analysts - Insider Monkey

Apr 29, 2026

Apr 29, 2026

BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Wednesday - MarketBeat

Apr 29, 2026

Apr 29, 2026

BCRX Forecast, Price Target & Analyst Ratings | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill

Apr 29, 2026

Apr 28, 2026

BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year - MSN

Apr 28, 2026

Apr 28, 2026

BioCryst to Present at Upcoming Investor Conferences - The Manila Times

Apr 28, 2026

Apr 28, 2026

BioCryst lines up two investor conference presentations in May and June - Stock Titan

Apr 28, 2026

Apr 27, 2026

Intellia Heads To FDA With Positive Phase III Results For Lonvo-Z - Citeline News & Insights

Apr 27, 2026

Apr 27, 2026

BioCryst To Acquire Astria Therapeutics In $700M Deal - MSN

Apr 27, 2026

Apr 27, 2026

MSN Money - MSN

Apr 27, 2026

Apr 26, 2026

BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN

Apr 26, 2026

Apr 26, 2026

BioCryst gains amid takeover speculation - MSN

Apr 26, 2026

Apr 25, 2026

The Technical Signals Behind (BCRX) That Institutions Follow - Stock Traders Daily

Apr 25, 2026

Apr 24, 2026

BCRX Price Today: BioCryst Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 24, 2026

Apr 23, 2026

[ARS] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan

Apr 23, 2026

Apr 23, 2026

BioCryst (BCRX) puts 7M-share incentive plan increase to stockholder vote - Stock Titan

Apr 23, 2026

Apr 23, 2026

BCRX (BioCryst Pharmaceuticals Inc.) drops 2.38 percent post Q4 2025 EPS miss despite 94 percent year over year revenue growth.Social Flow Trades - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 22, 2026

BCRX (BioCryst Pharmaceuticals Inc.) reports steep Q4 2025 EPS miss, stock edges 0.21 percent lower in daily trading.Analyst Ratings - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Apr 22, 2026

BCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 22, 2026

Apr 20, 2026

There's No Escaping BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Muted Revenues - 富途牛牛

Apr 20, 2026

Apr 20, 2026

BCRX Stock Price, Quote & Chart | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill

Apr 20, 2026

Apr 18, 2026

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 18, 2026

Apr 17, 2026

BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating - 富途牛牛

Apr 17, 2026

Apr 17, 2026

Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and BioCryst (BCRX) - The Globe and Mail

Apr 17, 2026

Apr 16, 2026

Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Apr 16, 2026

Apr 16, 2026

Is Hiring AI-Focused Rare Disease R&D Leader Sandeep Menon Altering The Investment Case For BioCryst (BCRX)? - Sahm

Apr 16, 2026

Apr 16, 2026

BioCryst to Report First Quarter 2026 Financial Results on May 6 - Sahm

Apr 16, 2026

Apr 15, 2026

BioCryst to File Peramivir NDA Supported by BARDA/HHS Funding - AOL.com

Apr 15, 2026

Apr 15, 2026

Lilly to acquire CrossBridge Bio for up to $300m - Pharmaceutical Technology

Apr 15, 2026

Apr 15, 2026

BioCryst to Report First Quarter 2026 Financial Results on May 6 | Nation/World | bdtonline.com - Bluefield Daily Telegraph

Apr 15, 2026